Related Experiment Video
Updated: Dec 31, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Gambogenic acid exerts anticancer effects in cisplatin‑resistant non‑small cell lung cancer cells
Daofu Shen1, Yu Wang2, Hongmei Niu3
1Department of Pathology, College of Combine Traditional Chinese and Western Medicine, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, P.R. China.
Abstract:
Non‑small cell lung cancer (NSCLC) is the most common type of lung cancer and the most common cause of mortality in patients with lung cancer. The efficacy of cisplatin‑based chemotherapy in NSCLC is limited by drug resistance, therefore, the development of novel anticancer agents is required to overcome cisplatin resistance. The present study investigated the anticancer activity of gambogenic acid (GNA), derived from gamboge, in the cisplatin‑resistant NSCLC cell line A549/Cis. GNA was revealed to have a potent inhibitory effect on cell growth in A549/Cis cells by blocking the cell cycle and inducing apoptosis. The investigation of the molecular mechanisms identified that GNA arrested the cell cycle at the G1 phase through the downregulation of cyclin Ds, cyclin dependent kinase (CDK)4 and CDK6, and the upregulation of p53 and p21. In addition, GNA induced apoptosis by increasing the activation of caspase 3 and caspase 7, in addition to the cleavage of poly(ADP‑ribose) polymerase. The results of the present study supported the potential application of GNA in cisplatin‑resistant NSCLC.
Insights
Gambogenic acid (GNA) shows potent anticancer activity against cisplatin-resistant non-small cell lung cancer (NSCLC). GNA inhibits cell growth by inducing apoptosis and cell cycle arrest, offering a potential new treatment for resistant NSCLC.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality.
- Cisplatin resistance limits the efficacy of current chemotherapy for NSCLC.
- Novel therapeutic agents are needed to overcome drug resistance in NSCLC.
Purpose of the Study:
- To investigate the anticancer activity of gambogenic acid (GNA) against cisplatin-resistant NSCLC cells.
- To elucidate the molecular mechanisms underlying GNA's effects on resistant NSCLC cells.
Main Methods:
- Utilized the cisplatin-resistant NSCLC cell line A549/Cis.
- Assessed GNA's effects on cell growth, cell cycle progression, and apoptosis.
- Analyzed key molecular markers including cyclins, cyclin-dependent kinases, p53, p21, caspases, and PARP.
Main Results:
- GNA demonstrated significant inhibition of cell growth in A549/Cis cells.
- GNA induced cell cycle arrest at the G1 phase by downregulating cyclin D, CDK4, and CDK6, and upregulating p53 and p21.
- GNA promoted apoptosis through increased activation of caspase 3 and caspase 7, and cleavage of PARP.
Conclusions:
- Gambogenic acid exhibits potent anticancer properties against cisplatin-resistant NSCLC.
- GNA's mechanism involves cell cycle arrest and induction of apoptosis.
- GNA holds potential as a novel therapeutic agent for overcoming cisplatin resistance in NSCLC.
More Related Videos
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
